glp 1 agonist alzheimer Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease Neuroprotective Actions of Glucagon-Like Peptide-1

At doses of 7 mg and 14 mg per day, it is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with that condition who are at high cardiovascular risk

Crossing the blood-brain barrier with nanoparticles

2 Genotype, soil chemistry, altitude, temperature, irrigation, and harvest timing can modulate secondary metabolite biosynthesis and produce chemotypes rich in either thymol or carvacrol

By encouraging the body to tap into its own hormone production capabilities, sermorelin therapy offers a unique approach to addressing growth hormone deficiency

Cervical disc problems and thoracic outlet syndrome can mimic rhomboid strain but require different treatment approaches